RONALD GARB: Open Payments
NPI 1891776167 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,964 in 95 payments from 17 companies in 2025. Trend: 2023 $1,319 · 2024 $1,709 · 2025 $1,964
Food & beverage: $1,944Education: $19
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $333 |
| Neurocrine BioSciences, Inc. | 9 | $232 |
| Teva Pharmaceuticals USA, Inc. | 13 | $218 |
| Otsuka America Pharmaceutical, Inc. | 11 | $202 |
| Corium, LLC | 6 | $180 |
| ABBVIE INC. | 11 | $156 |
| Alkermes, Inc. | 5 | $109 |
| Axsome Therapeutics, Inc. | 5 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $61 |
Products named: CAPLYTA, INGREZZA, REXULTI, Azstarys, AUSTEDO XR, VRAYLAR, ARISTADA, Auvelity.
Industry payments across TX — which companies pay providers there.
